Johnson & Johnson (JNJ) Sees FY13 Revs at $70.4B - $71.1B; Est. at $71.1B
Tweet
Share
E-mailGet Alerts JNJ Hot Sheet
Price: $269.99 -0.09%
EPS Growth %: +2.9%
Financial Fact:
Interest income: -97M
Today's EPS Names:
VIVO, OCCI, ALZN, More
EPS Growth %: +2.9%
Financial Fact:
Interest income: -97M
Today's EPS Names:
VIVO, OCCI, ALZN, More
Join SI Premium – FREE
Johnson & Johnson (NYSE: JNJ) sees FY13 sales of $70.4 billion to $71.1 billion. The Street is currently at about $71.1 billion.
Earlier, the
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
Earlier, the
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Nucor projects Q3 2026 earnings above prior year, below estimates
- Johnson & Johnson's RYBREVANT® (amivantamab-vmjw) plus chemotherapy delivers longest reported median overall survival in EGFR exon 20 insertion mutation-positive lung cancer
- CoreWeave Added Over $25B Net New Customer Commitments Early In 3Q
Create E-mail Alert Related Categories
Guidance, Hot GuidanceSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
